Despite the impact from the novel coronavirus (Covid-19) lockdown measures, UOB KayHian is still bullish on Tianjin Zhong Xin Pharmaceutical Group Corp. “We expect a strong rebound in 2H20 as China’s economy recovers and reopens,” UOBKH analysts Llelleythan Tan and John Cheong write in a note ...

SINGAPORE (Aug 14): Tianjin Zhong Xin Pharmaceutical Group Corporation has recorded earnings of RMB 156.9 million ($30.8 million) or 0.20 RMB cents per share for the 2Q19 ended June, some 10% higher than earnings of RMB 142.2 million a year ago. 2Q19 revenue rose 19% to RMB 1.78 billion, compared t...

THE following companies saw new developments that may affect trading of their shares on Monday:

TIANJIN Zhong Xin Pharmaceutical Group has posted a net profit of 567.8 million yuan (S$114.7 million) for FY2018, up 20 per cent from 473.3 million yuan a year ago, lifted by interest income and gains from associated companies Sino-American Tianjin Smithkline & French Lab and Tianjin Ho...